Prosecution Insights
Last updated: April 19, 2026

Examiner: DRISCOLL, LORA E BARNHART

Tech Center 3900 • Art Units: 1600 1651 1653 3991

This examiner grants 31% of resolved cases

Performance Statistics

30.9%
Allow Rate
-29.1% vs TC avg
411
Total Applications
+19.6%
Interview Lift
1824
Avg Prosecution Days
Based on 388 resolved cases, 2023–2026

Rejection Statute Breakdown

3.7%
§101 Eligibility
18.6%
§102 Novelty
23.8%
§103 Obviousness
31.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18189147 MOLECULAR RHEOSTAT FOR COFACTOR BALANCE Final Rejection The Regents of the University of California
18414545 THERAPEUTIC AGENT FOR MALIGNANT TUMORS EXPRESSING MHC CLASS II Non-Final OA Juntendo Educational Foundation
18547471 ANTIBODIES, FRAGMENTS OR DERIVATIVES SPECIFICALLY BINDING TO A PROTEIN ANTIGEN CAPABLE OF BINDING TO NUCLEIC ACIDS AND USES OF SAME Non-Final OA COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
18774363 NANOEMULSION COMPOSITIONS OF TAXOID DRUGS, AND METHODS FOR THE USE THEREOF TO TARGET CANCER CELLS AND CANCER STEM CELLS Final Rejection Northeastern University
18272168 CD64 CHIMERIC RECEPTOR AND USES THEREOF Non-Final OA CONSIGLIO NAZIONALE DELLE RICERCHE
18131746 TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS Non-Final OA MARY KAY INC.
17073828 Variants of C-Type Natriuretic Peptide Final Rejection BIOMARIN PHARMACEUTICAL INC.
18281884 VIRAL VECTOR-DERIVED TARGET PROTEIN FOR ANTICANCER THERAPY AND BINDING MOLECULE OR FRAGMENT THEREOF SPECIFICALLY BINDING THERETO Non-Final OA BIONOXX INC.
18264191 THERAPEUTIC COMBINATION AND USE THEREOF Non-Final OA Akeso Pharmaceuticals, Inc.
18355451 TAFA4 Compounds and Uses Thereof for Treating Pain Non-Final OA Universite D'Aix-Marseille
18223979 SYSTEM AND METHOD FOR AUTOMATED DETECTION AND MONITORING OF DYSPLASIA AND ADMINISTRATION OF IMMUNOTHERAPY AND CHEMOTHERAPY Non-Final OA VISIONGATE, INC.
18031479 METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA Non-Final OA IMMUNOVACCINE TECHNOLOGIES INC.
18130112 ACTIVATABLE IL2 COMPOSITION AND METHODS OF USE Non-Final OA Immune Targeting, Inc.
18102588 AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY Final Rejection Universite de Mons
18001058 METHOD OF PRODUCING CARDIOMYOCYTE POPULATION, METHOD OF PROLIFERATING CARDIOMYOCYTES, CARDIOMYOCYTE POPULATION, TRANSPLANTATION MATERIAL, MULTINUCLEATED CARDIOMYOCYTE, AND KIT FOR PROLIFERATING CARDIOMYOCYTES Non-Final OA Myoridge Co. Ltd.
17984985 ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS Non-Final OA Helixmith Co., Ltd

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month